Palo Alto Investors LP Taysha Gene Therapies, Inc. Call Options Transaction History
Palo Alto Investors LP
- $856 Million
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TSHA
# of Institutions
111Shares Held
109MCall Options Held
108KPut Options Held
158K-
Avoro Capital Advisors LLC New York, NY18.7MShares$40.3 Million0.65% of portfolio
-
Rtw Investments, LP New York, NY18.6MShares$40.2 Million0.86% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$19.4 Million2.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.92MShares$12.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY5.17MShares$11.2 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $104M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...